Shawn Iadonato

CEO, Kineta

Shawn Iadonato, Ph.D., serves as Kineta's chief executive officer. He is a co-founder of Kineta and previously served as chief scientific officer. Under his leadership as CSO, the Kineta pipeline expanded to include the AviiD Screening Platform and five novel drug and vaccine programs with a focus on autoimmune diseases, antivirals, and chronic pain.

Prior to founding Kineta, Shawn co-founded and served as CSO of Illumigen Biosciences Inc. At Illumigen Biosciences, he pioneered its patented drug discovery platform, which relied upon recruitment and screening of healthy populations and elucidation of their shared "wellness" genes. Shawn also led the successful discovery and preclinical development of Illumigen's anti-hepatitis C drug, which ultimately led to the sale of the company in December 2007 to Cubist Pharmaceuticals (now part of Merck & Co.).

Before Illumigen, Shawn managed the Human Genome Center at the University of Washington. He is co-inventor on more than 35 US patents or patent applications. He is principal investigator or co-investigator on numerous ongoing government grants and contracts.

Shawn received a Ph.D. in Genetics from the University of Washington and is a graduate of the University of Pennsylvania.


Share this: Share on Facebook Tweet about this on Twitter Share on Google+ Share on LinkedIn Email this to someone

News for: Shawn Iadonato

Speaker at FiRe 2016

News Headlines
Samsung Biologics, Kineta Enter Development and Manufacturing Agreement
Posted on 20 Jul 2021 at 7:19am

Kineta Announces Successful Completion of Pre-IND Meeting with the FDA for KV...
Posted on 27 Jul 2021 at 7:39am

Kineta and Samsung Biologics sign agreement for development and manufacture o...
Posted on 20 Jul 2021 at 6:42am

Samsung Biologics Partners with Kineta for Anti-VISTA Antibody Immunotherapy
Posted on 21 Jul 2021 at 1:34pm

Kineta and Samsung Biologics Announce Development and Manufacturing Agreement...
Posted on 20 Jul 2021 at 12:59am

Kineta and Samsung Biologics Announce Development and Manufacturing Agreement...
Posted on 20 Jul 2021 at 4:17pm

Kineta and Samsung Biologics Announce Development and Manufacturing Agreement...
Posted on 20 Jul 2021 at 5:04am



News feeds courtesy of:

FiRe 2016 Media


Bleeding-Edge Medicine: Today's Discoveries, Tomorrow's Practice



Share this video: Share on Facebook Tweet about this on Twitter Share on Google+ Share on LinkedIn Email this to someone